Circio logoCircio logo

  • About
      • About Circio
      • CEO Statement
      • Pipeline
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
  • circRNA
      • Circio AB
      • circVec platform
  • Clinical programs
      • ONCOS-102
      • KRAS program
      • Publications
  • Partnering
  • Investors
      • Press releases
      • Events
      • Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
      • Contact
  • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
  • Contacts
    • About
      • About Circio
      • CEO Statement
      • Our pipeline
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
    • circRNA
      • Circio AB
      • circVec platform
    • Clinical programs
      • ONCOS-102
      • KRAS program
      • Publications
    • Partnering
      • Partnering
    • Investors
      • Press releases
      • Events
      • Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
      • General Meetings
      • Board of Directors
      • Nomination Committee
      • Committees
      • Management
      • Articles of Association
      • Contact
      • Subscribe
      • Contact
    • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
    • Contacts
      • Offices
      • Investors & Media
    All press releases
    • Press releases - Regulatory
    • Press releases - Non-regulatory
    2018
    • 2023
    • All years
    All subjects
    • Corporate news
    • Other
    All languages
    • English
    • Norwegian
    December 12, 2018
    Press release - Regulatory

    Targovax Presents at DNB 9th Annual Nordic Healthcare Conference

    November 28, 2018
    Press release - Non-regulatory

    Targovax is invited to present at upcoming investor and industry conferences

    November 16, 2018
    Press release - Non-regulatory

    Targovax to present at NeoAg Summit 2018

    November 1, 2018
    Press release - Regulatory

    Targovax ASA: Third quarter 2018 results

    October 26, 2018
    Press release - Regulatory

    Targovax ASA: Announcement of third quarter 2018 financial results

    October 15, 2018
    Press release - Non-regulatory

    Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer

    October 12, 2018
    Press release - Regulatory

    Agenda for Targovax Capital Markets Day 15 October 2018, in Oslo, Norway

    October 11, 2018
    Press release - Regulatory

    Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City today, 11 October, 2018

    October 4, 2018
    Press release - Regulatory

    Targovax to host Capital Markets Day 15 October 2018, in Oslo, Norway

    October 1, 2018
    Press release - Regulatory

    Targovax presented ONCOS-102 poster at 13th International Adenovirus Meeting

    September 27, 2018
    Press release - Regulatory

    Targovax announces interim results from Phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma

    September 27, 2018
    Press release - Regulatory

    Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018

    September 25, 2018
    Press release - Regulatory

    Targovax ASA: Issuance of options to primary insider

    September 13, 2018
    Press release - Regulatory

    Targovax strengthens management team with the appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO

    September 12, 2018
    Press release - Regulatory

    Targovax announces publication of new oncolytic virus data in the Journal of Medical Virology and Cancer Gene Therapy

    September 4, 2018
    Press release - Regulatory

    Targovax ASA: Registration of new share capital following settlement of restricted stock units

    August 29, 2018
    Press release - Regulatory

    Targovax ASA: Settlement of restricted stock units and resolution to increase the share capital

    August 23, 2018
    Press release - Regulatory

    Targovax ASA: Second quarter and first half year 2018 results

    August 15, 2018
    Press release - Regulatory

    Targovax ASA: Invitation to second quarter and first half year 2018 results presentation Thursday 23 August

    July 12, 2018
    Press release - Regulatory

    Targovax and SOTIO announce first patient dosed in Phase I/II combination trial of ONCOS-102 with DCVAC

    June 20, 2018
    Press release - Regulatory

    Targovax ASA: Mandatory notification of trade – primary insider

    June 19, 2018
    Press release - Regulatory

    Targovax granted EU Patent for mutant-RAS neoantigen platform 2nd generation product TG02

    June 12, 2018
    Press release - Regulatory

    Targovax hosts conference call 12 June 2018

    June 11, 2018
    Press release - Regulatory

    Targovax strengthens focus on ONCOS oncolytic virus development program

    June 4, 2018
    Press release - Regulatory

    Targovax to Present at Jefferies 2018 Global Healthcare Conference

    May 24, 2018
    Press release - Regulatory

    Targovax strengthens 2-year survival rate in resected pancreatic cancer with TG01

    May 16, 2018
    Press release - Regulatory

    Targovax to present at upcoming investor and industry conferences

    May 3, 2018
    Press release - Regulatory

    Targovax ASA: First quarter 2018 results

    May 2, 2018
    Press release - Regulatory

    Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma

    April 25, 2018
    Press release - Regulatory

    Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

    April 25, 2018
    Press release - Non-regulatory

    Targovax presentation at ChinaBio Partnering Forum 2018

    April 24, 2018
    Press release - Regulatory

    Targovax ASA: Invitation to first quarter 2018 results presentation Thursday 3 May

    April 12, 2018
    Press release - Regulatory

    Targovax strengthens Board of Directors with the appointment of Catherine Wheeler

    April 11, 2018
    Press release - Regulatory

    Targovax ASA: Protocol from the Annual General Meeting

    March 24, 2018
    Press release - Regulatory

    Targovax ASA: Proposal from the nomination committee to the annual general meeting 11 April 2018

    March 15, 2018
    Press release - Regulatory

    Targovax ASA: Notice of Annual General Meeting

    March 15, 2018
    Press release - Regulatory

    Targovax ASA: Annual Report 2017

    March 1, 2018
    Press release - Regulatory

    Targovax ASA: Issuance of restricted stock unites (RSUs) to the chairman of the board of directors

    February 27, 2018
    Press release - Non-regulatory

    Targovax to present at Biologics World Nordic 2018

    February 15, 2018
    Press release - Regulatory

    Targovax ASA: Fourth quarter and full year 2017 results

    February 7, 2018
    Press release - Regulatory

    Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma

    February 6, 2018
    Press release - Regulatory

    Targovax ASA: Invitation to fourth quarter and full year 2017 results presentation Thursday 15 February

    February 2, 2018
    Press release - Regulatory

    Targovax ASA: Exercise price of options

    February 1, 2018
    Press release - Regulatory

    Targovax ASA issues options to employees

    January 8, 2018
    Press release - Regulatory

    Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer

    January 4, 2018
    Press release - Regulatory

    Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients

    IR contact
    Dr Lubor Gaal
    Dr Lubor Gaal
    Chief Financial Officer
    lubor.gaal@circio.com
    (+34) 683 343 811
    Renate Birkeli
    Renate Birkeli
    Investor Relations
    renate.birkeli@circio.com
    (+47) 922 61 624
    Circio logo

    Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

    • About
    • circRNA
    • Clinical programs
    • Partnering
    • Investors
    • Media
    • Contacts

    CONTACT

    Circio Holding ASA
    Email: contact@circio.com

    • Cookies
    • Privacy policy
    • STAY CONNECTED